Ranitidine

Overview

Ranitidine, sold under the brand name Zantac among others, is a medication used to decrease stomach acid production. It is used in the treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. It can be given by mouth, injection into a muscle, or injection into a vein.[1] WP

In September 2019, the probable carcinogen N-nitrosodimethylamine (NDMA) was discovered in ranitidine products from a number of manufacturers, resulting in recalls. In April 2020, ranitidine was withdrawn from the United States market and suspended in the European Union and Australia due to these concerns. A reformulated ranitidine was approved in Australia in October 2024, and in the United States in November 2025.[2–15] WP

Common side effects include headaches, and pain or burning sensation if given by injection. Serious side effects may include cancer, liver problems, a slow heart rate, pneumonia, and the potential of masking stomach cancer. It is also linked to an increased risk of Clostridioides difficile colitis. Ranitidine is an H₂ histamine receptor antagonist that works by blocking histamine, thus decreasing the amount of acid released by cells of the stomach.[1][16][17] WP

Ranitidine was discovered in England in 1976 and came into commercial use in 1981. It is on the World Health Organization's List of Essential Medicines.[18][19] WP

Uses, dosage and effects

Medical uses

• Relief of heartburn[20] WP
• Short-term and maintenance therapy of gastric and duodenal ulcers[20] WP
• With nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce the risk of ulceration Proton-pump inhibitors (PPIs) are more effective for the prevention of NSAID-induced ulcers.[20][21] WP
• Pathologic gastrointestinal (GI) hypersecretory conditions such as Zollinger–Ellison syndrome WP
• Gastroesophageal reflux disease (GORD or GERD) WP
• Erosive esophagitis WP
• Part of a multidrug regimen for Helicobacter pylori eradication to minimise the risk of duodenal ulcer recurrence WP
• Recurrent postoperative ulcer WP
• Upper GI bleeding WP
• For prevention of acid-aspiration pneumonitis during surgery, it can be administered preoperatively. The drug increases gastric pH, but generally has no effect on gastric volume. In a 2009 meta-analysis comparing the net benefit of PPIs and ranitidine to reduce the risk of aspiration before anaesthesia, ranitidine was found to be more effective than PPIs in reducing the volume of gastric secretions. Ranitidine may have an anti-emetic effect when administered preoperatively.[22] WP
• Prevention of stress-induced ulcers in critically ill patients[23] WP
• Used together with diphenhydramine as secondary treatment for anaphylaxis; after first-line epinephrine.[24][25] WP

Risks and side effects

Adverse effects

These adverse effects for ranitidine have been reported as events in clinical trials: WP

Central nervous system

Rare reports have been made of ranitidine causing malaise, dizziness, somnolence, insomnia, and vertigo. In severely ill, elderly patients, cases of reversible mental confusion, agitation, depression, and hallucinations have been reported.[20] WP

Cardiovascular

Arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats have also been reported.[20] WP

Gastrointestinal

Drugs in the H₂ receptor blocker class of medicines have the potential to cause vitamin B₁₂ deficiency, secondary to a reduction in food-bound vitamin B₁₂ absorption. Elderly patients taking H₂ receptor antagonists are more likely to require B₁₂ supplementation than those not taking such drugs. H₂ blockers may also reduce the absorption of drugs (azole antifungals, calcium carbonate) that require an acidic stomach. In addition, multiple studies suggest the use of H₂ receptor antagonists such as ranitidine may increase the risk of infectious diarrhoea, including traveller's diarrhoea and salmonellosis. A 2005 study found that by suppressing acid-mediated breakdown of proteins, ranitidine may lead to an elevated risk of developing food or drug allergies, due to undigested proteins then passing into the GI tract, where sensitisation occurs. Patients who take these agents develop higher levels of immunoglobulin E against food, whether they had prior antibodies or not. Even months after discontinuation, an elevated level of IgE in 6% of patients was still found in the study.[26–34] WP⚠ Wikipedia itself has flagged this text: medical citation needed.

Liver

Cholestatic hepatitis, liver failure, hepatitis, and jaundice have been noted, and require immediate discontinuation of the drug. Blood tests can reveal an increase in liver enzymes or eosinophilia, although in rare instances, severe cases of hepatotoxicity may require a liver biopsy.[20][35] WP

Lungs

Ranitidine and other histamine H₂ receptor antagonists may increase the risk of pneumonia in hospitalised patients. Ranitidine increases the risk of community-acquired pneumonia in adults and children.[36][37][38] WP

Blood

Thrombocytopenia is a rare but known side effect. Drug-induced thrombocytopenia usually takes weeks or months to appear, but may appear within 12 hours of drug intake in a sensitised individual. Typically, the platelet count falls to 80% of normal, and thrombocytopenia may be associated with neutropenia and anemia.[39] WP

Skin

Rash, including rare cases of erythema multiforme, and rare cases of hair loss and vasculitis have been seen.[20] WP

Disease-related concerns

Relief of symptoms due to the use of ranitidine does not exclude the presence of a gastric malignancy. In addition, with kidney or liver impairment, ranitidine must be used with caution. It should be avoided in patients with porphyria, as it may precipitate an attack.[40][41] WP

Children

In children, the use of gastric acid inhibitors has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia. A cohort analysis including over 11,000 neonates reported an association of H₂ blocker use, and an increased incidence of necrotizing enterocolitis in very-low-birth-weight (VLBW) neonates. In addition, about a six-fold increase in mortality, necrotizing enterocolitis, and infection such as sepsis, pneumonia, urinary tract infection was reported in patients receiving ranitidine in a cohort analysis of 274 VLBW neonates.[37][42][43] WP

Drug tests

Ranitidine may return a false positive result with some commercial urine drug screening kits for testing for drugs of abuse.[44] WP

Cancer-causing due to inherent instability

In June 2019, Valisure informed the US Food and Drug Administration (FDA) that Zantac-branded and generic ranitidine resulted in very high levels of NDMA in the human body "due to an inherent instability of the ranitidine molecule".[45][46] WP

In September 2019, the FDA acknowledged that ranitidine medicines, including some products sold under the brand name Zantac, contained a nitrosamine impurity called N-nitrosodimethylamine (NDMA), classified as a probable human carcinogen, at unacceptable levels. Health Canada announced that it was assessing NDMA in ranitidine and requested that manufacturers stop the distribution of ranitidine products in Canada until the NDMA levels in the products are found to be safe. Health Canada announced that ranitidine drugs were being recalled by Sandoz Canada, Apotex Inc., Pro Doc Limitée, Sanis Health Inc., and Sivem Pharmaceuticals ULC. The European Medicines Agency (EMA) started a European Union-wide review of ranitidine medicines at the request of the European Commission.[2][3][4][6][47][48][49] WP

In October 2019, the US FDA observed that the third-party laboratory that found very high levels of NDMA was using higher temperatures in its tests to detect nitrosamine impurities. The NDMA was mostly generated by the added heat, but the higher temperatures are recommended for using a gas chromatography–mass spectrometry method to test for NDMA in valsartan and angiotensin II receptor blockers. The FDA stated that it recommends using a Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) testing protocol to test samples of ranitidine. Its LC-HRMS testing method does not use elevated temperatures, and has shown the presence of much lower levels of NDMA in ranitidine medicines than were reported by the third-party laboratory. International regulators using similar LC-MS testing methods have also shown the presence of lower but still unacceptable levels of NDMA in ranitidine samples. The FDA provided additional guidance about using another LC-MS method based on a triple-quadrupole MS platform.[5][50][51][52] WP

In September 2019, Sandoz issued a "precautionary distribution stop" of all medicines containing ranitidine, followed a few days later by a recall of ranitidine hydrochloride capsules in the United States. The Italian Medicines Agency recalled all ranitidine that uses an active pharmaceutical ingredient from Saraca Laboratories. The Federal Union of German Associations of Pharmacists (Arzneimittelkommission der Deutschen Apotheker) published a list of recalled products, as did the Therapeutic Goods Administration in Australia.[53–62] WP

In November 2019, the FDA stated that its tests found levels of NDMA in ranitidine and nizatidine that are similar to those that one may typically ingest with common foods such as grilled or smoked meats. The FDA also stated that its simulated gastric fluid model tests and simulated intestinal fluid model tests indicated that NDMA is not formed when exposed to acid in the stomach with a normal diet. The FDA advised companies to recall their ranitidine if testing shows levels of NDMA above the acceptable daily intake (96 nanograms per day or 0.32 parts per million for ranitidine). At the same time, it indicated that some levels of NDMA found in medicines still exceeded the agency's acceptable levels.[5][63][64] WP

In December 2019, the FDA asked manufacturers of ranitidine and nizatidine products to expand their NDMA testing to include all lots of the medication before making them available to consumers.[5] WP

By the end of 2019, ranitidine had already fallen from the 40th most commonly prescribed medication in the United States in 2018, to 53rd place for 2019, with about 13.6 million prescriptions for the year, versus nearly 19 million the previous year. This reflects total prescriptions for all of 2019, while safety concerns affected sales in only the final 4 months of the year.[65] WP

In April 2020, FDA testing and evaluation prompted by information from third-party laboratories confirmed that NDMA levels increase in ranitidine even under normal storage conditions, and NDMA has been found to increase significantly in samples stored at higher temperatures, including those at which the product may be exposed during distribution and handling by consumers. The testing also showed that the level of NDMA increases as ranitidine medication ages. These conditions may raise the NDMA level above the acceptable daily intake limit. The EMA completed and issued their EU-wide review at the end of the month and the European Commission suspended all ranitidine products in the EU.[7][8] WP

In August 2020, the EMA provided guidance to marketing authorization holders for avoiding the presence of nitrosamine impurities and asked them to review all chemical and biological human medicines for the presence of nitrosamines and to test the products at risk. In September 2020, the FDA issued guidance about the control of nitrosamine impurities in human drugs. An implementation plan was issued in February 2021.[66–70] WP

In 2022, cancer concerns were found in a Taiwanese nationwide population study.[71] WP

The FDA issued revised guidelines about nitrosamine impurities in September 2024.[69] WP

List of recalls

In September 2019, Apotex recalled all over-the-counter ranitidine tablets sold in the United States at Walmart, Rite Aid, and Walgreens. These retailers, along with CVS, removed Zantac and some generics from their shelves.[72–78] WP

In October 2019, the UK Medicines and Healthcare products Regulatory Agency issued a drug alert for ranitidine "... to proactively communicate the recall to hospitals, pharmacies, dispensing practices, retailers and wholesalers in the UK." This included all Zantac-branded preparations, along with all generic preparations of ranitidine from Teva UK Limited, Rosemont Pharmaceuticals Limited, Omega Pharma Limited and Galpharm International Limited, Perrigo Company plc, Creo Pharma Limited and Tillomed Laboratories Limited, OTC Concepts Ltd, Relonchem Ltd, Noumed Life Sciences Ltd, and Medreich Plc., Accord Healthcare, Medley Pharma Limited, and Medreich Plc.[79–93] WP

In October 2019, the UK Department of Health and Social Care issued a supply distribution alert (SDA/2019/005) for all oral formulations of ranitidine.[94] WP

In October 2019, Sanofi recalled all over-the-counter Zantac in the United States and Canada, Perrigo issued a worldwide recall of ranitidine, Dr. Reddy's issued a recall of all ranitidine products in the United States, and Novitium Pharma recalled all ranitidine hydrochloride capsules in the US.[5][95–99] WP

In November 2019, Aurobindo Pharma, Amneal Pharmaceuticals, American Health Packaging, Golden State Medical Supply, and Precision Dose recalled some lots of ranitidine tablets, capsules, and syrup.[100–104] WP

In December 2019, Glenmark Pharmaceutical recalled some lots of ranitidine tablets.[105] WP

In January 2020, Appco Pharma and Northwind Pharmaceuticals recalled some lots of ranitidine tablets and capsules.[106][107] WP

In February 2020, American Health Packaging recalled some lots of ranitidine tablets manufactured by Amneal Pharmaceuticals.[108] WP

In April 2020, the FDA requested a manufacturer's market withdrawal of ranitidine, meaning that ranitidine products would not be available for prescription or over-the-counter sale in the US.[6][7][109] WP

In April 2020, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the suspension of all ranitidine medicines in the European Union because of the presence of unacceptable levels of NDMA.[8][9][110] WP

A ranitidine manufacturer requested a re-examination of the decision, but in December 2020, the EMA confirmed its recommendation to suspend all ranitidine medicines in the European Union. The UK National Health Service (NHS) Web site as of December 2021 said "Ranitidine is not currently available in the UK or globally... It's not yet known whether it will be available again in future." A March 2024 review left the message up.[9][111] WP

In 2021, Solara Active Pharma Sciences, which supplies ranitidine active pharmaceutical ingredient (API), said that it had mitigated the risks of the formation of NDMA during the manufacturing of ranitidine API. The company was granted a revised certificate by the European Directorate for the Quality of Medicines and Healthcare, which proves that the API complies with certain European rules. GlaxoSmithKline, Sanofi, and Teva said they had no plans to reintroduce the drug in the EU, but Accord Healthcare considered the possible reintroduction of ranitidine. However a control strategy regarding NDMA formation through the end of the product's shelf life, despite heat, time and digestion due to endogenous formation from the API, would be required.[112] WP

Pharmacology

Mechanism of action

Ranitidine is a competitive, reversible inhibitor of the action of histamine at the histamine H₂ receptors found in gastric parietal cells. This results in decreased gastric acid secretion and gastric volume, and reduced hydrogen ion concentration. Ranitidine's acid-lowering effect is more pronounced for basal and nocturnal acid secretion than it is for food-stimulated acid secretion. Additional indirect effects of ranitidine are decreased pepsin secretion and increased nitrate-reducing bacterial flora.[113] WP

In preclinical studies, ranitidine has also demonstrated immunomodulatory effects; in mouse models of breast cancer, ranitidine inhibited tumor growth through a B cell-dependent mechanism associated with enhanced antitumor antibody responses.[114] WP

Pharmacokinetics

Oral absorption: 50%[113] WP

Protein binding: 15%[115] WP

Metabolism: The major metabolite in the urine is ranitidine N-oxide, which represents less than 4% of the dose. Other metabolites of ranitidine include ranitidine S-oxide (1%) and desmethyl ranitidine (1%).[20] WP

Half-life elimination: With normal renal function, ranitidine taken orally has a half-life of 2.5–3.0 hours. If taken intravenously, the half-life is generally 2.0–2.5 hours in a patient with normal kidney function and normal creatinine clearance. In people with kidney dysfunction, the half-life may increase to 4 to 5 hours.[113] WP⚠ Wikipedia itself has flagged this text: medical citation needed.

Excretion: The primary route of excretion is the urine. In addition, about 30% of the orally administered dose is collected in the urine as unabsorbed drug in 24 hours.[20][113] WP

Elderly

In the elderly population, the plasma half-life of ranitidine is prolonged to 3–4 hours secondary to decreased kidney function causing decreased clearance.[20] WP

Children

In general, studies of children aged 1 month to 16 years of age have shown no significant differences in pharmacokinetic parameter values in comparison to healthy adults, when correction is made for body weight.[20] WP

History

History

Ranitidine was first prepared in England as AH19065 by John Bradshaw in the summer of 1977 in the Ware research laboratories of Allen and Hanburys, part of the former Glaxo organisation. Its development was a response to the first in class histamine H₂ receptor antagonist, cimetidine, developed by Sir James Black at Smith, Kline and French, and launched in the United Kingdom as Tagamet in November 1976. Both companies eventually merged as GlaxoSmithKline (GSK), following a sequence of mergers and acquisitions, starting with the integration of Allen and Hanbury's Ltd and Glaxo to form Glaxo Group Research in 1979, and ultimately with the merger of Glaxo Wellcome and SmithKline Beecham in 2000. Ranitidine was the result of a rational drug-design process using what was by then a fairly refined model of the histamine H₂ receptor and quantitative structure-activity relationships.[116][117] WP

Glaxo refined the model further, by replacing the imidazole ring of cimetidine with a furan ring with a nitrogen-containing substituent, and in doing so developed ranitidine. Ranitidine was found to have a far-improved tolerability profile (i.e. fewer adverse drug reactions), longer-lasting action, and 10 times the activity of cimetidine. Ranitidine has 10% of the affinity that cimetidine has to CYP450, so it causes fewer side effects, but other H₂ blockers famotidine and nizatidine have no CYP450 significant interactions.[118] WP

Ranitidine was introduced in 1981, and was the world's biggest-selling prescription drug by 1987. Subsequently, it was largely superseded by the more effective proton-pump inhibitor (PPI) class of drugs, with omeprazole becoming the biggest-selling drug for many years. When omeprazole and ranitidine were compared in a study of 144 people with severe inflammation and erosions or ulcers of the oesophagus, 85% of those treated with omeprazole healed within eight weeks, compared with 50% of those given ranitidine. In addition, the omeprazole group reported earlier relief of heartburn symptoms.[119][120][121] WP⚠ Wikipedia itself has flagged this text: citation needed.

In September 2019, the probable carcinogen N-nitrosodimethylamine (NDMA) was discovered in ranitidine products from a number of manufacturers, resulting in recalls; in April 2020, it was withdrawn from the United States market and suspended in Europe and Australia. NDMA is a possible carcinogen and has been detected as an environmental contaminant.[122] WP

In 2024, ranitidine was re-approved for sale in Australia after the local sponsor of Zantac changed suppliers and tablet formulation. The new formulation was demonstrated to be stable throughout its shelf life and that nitrosamines are controlled within internationally established acceptable intake limits applied to the maximum daily dose.[13][14] WP

Chemistry

Formula

C13H22N4O3S PC

CAS number

82530-72-1 PC

Molar mass (g/mol)

314.41 PC

IUPAC name (computed by PubChem)

(E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine PC

SMILES

CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C PC

InChIKey

VMXUWOKSQNHOCA-UKTHLTGXSA-N PC

PubChem CID

3001055

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Ranitidine hydrochloride monograph
2. Other Health Canada assessing NDMA in ranitidine. 13 September 2019
3. Journal / agency Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. 13 September 2019
4. Journal / agency EMA to provide guidance on avoiding nitrosamines in human medicines. 13 September 2019
5. Journal / agency FDA updates and press announcements on NDMA in Zantac (ranitidine). 28 October 2019
6. Journal / agency Questions and Answers: NDMA impurities in ranitidine (commonly known as Zantac). 11 October 2019
7. Journal / agency FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. 1 April 2020
8. Journal / agency Suspension of ranitidine medicines in the EU. 30 April 2020
9. Journal / agency Ranitidine-containing medicinal products. 30 April 2020
10. Other Ranitidine. 2 April 2020
11. Journal / agency Wagner JA, Dinh JC, Lightdale JR, Gold BD, Colombo JM. Is this the end for ranitidine? NDMA presence continues to confound. Clinical and Translational Science. July 2021. doi:10.1111/cts.12995 · PMID 33934515 · PMC8301580
12. Other Over-the-counter (OTC) medicine monograph: Ranitidine hydrochloride. 16 October 2024
13. Other Gloria L. Zantac reinstated in Australian market. 1 October 2024
14. Other Application
15. Journal / agency FDA Approves Reformulated Ranitidine Following Comprehensive Safety Review. 25 November 2025
16. Other Zantac's Maker Kept Quiet About Cancer Risks for 40 Years. 15 February 2023
17. Journal / agency Tleyjeh IM, Abdulhak AB, Riaz M, Garbati MA, Al-Tannir M, Alasmari FA, Alghamdi M, Khan AR, Erwin PJ, Sutton AJ, Baddour LM. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLOS ONE. 2013. doi:10.1371/journal.pone.0056498 · PMID 23469173 · PMC3587620
18. Other Fischer J, Ganellin CR. Analogue-based Drug Discovery. 2006
19. Journal / agency World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. 2025. doi:10.2471/B09474
20. Journal / agency Ranitidine Hydrochloride. August 2020
21. Other Reflux Remedies: ranitidine
22. Journal / agency Clark K, Lam LT, Gibson S, Currow D. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia. June 2009. doi:10.1111/j.1365-2044.2008.05861.x · PMID 19453319
23. Journal / agency Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Medicine. February 2013. doi:10.1007/s00134-012-2769-8 · PMID 23361625 · PMC2249616
24. Journal / agency Tang AW. A practical guide to anaphylaxis. American Family Physician. October 2003. PMID 14567487
25. Other Anaphylaxis: Diagnosis and Management in the Rural Emergency Department
26. Journal / agency Force RW, Nahata MC. Effect of histamine H2-receptor antagonists on vitamin B12 absorption. The Annals of Pharmacotherapy. October 1992. doi:10.1177/106002809202601018 · PMID 1358279
27. Journal / agency Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. Journal of Clinical Epidemiology. May 2001. doi:10.1016/S0895-4356(00)00340-1 · PMID 11337218
28. Other Reflux Remedies: ranitidine
29. Journal / agency Cobelens FG, Leentvaar-Kuijpers A, Kleijnen J, Coutinho RA. Incidence and risk factors of diarrhoea in Dutch travellers: consequences for priorities in pre-travel health advice. Tropical Medicine & International Health. November 1998. PMID 9855403
30. Journal / agency Neal KR, Briji SO, Slack RC, Hawkey CJ, Logan RF. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ. January 1994. doi:10.1136/bmj.308.6922.176 · PMID 7906170 · PMC2542523
31. Journal / agency Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ. February 1996. doi:10.1136/bmj.312.7028.414 · PMID 8601113 · PMC2350063
32. Journal / agency Wickramasinghe LS, Basu SK. Salmonellosis during treatment with ranitidine. BMJ. 1984. doi:10.1136/bmj.289.6454.1272
33. Journal / agency Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. March 1980. doi:10.1016/s0140-6736(80)92826-3 · PMID 6103090
34. Journal / agency Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, Riemer AB, Ankersmit HJ, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB Journal. April 2005. doi:10.1096/fj.04-3170fje · PMID 15671152
35. Journal / agency Ranitidine: Hepatotoxicity. 28 June 2016
36. Journal / agency Mallow S, Rebuck JA, Osler T, Ahern J, Healey MA, Rogers FB. Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients?. Current Surgery. 2004. doi:10.1016/j.cursur.2004.03.014 · PMID 15475094
37. Journal / agency Canani RB, Cirillo P, Roggero P, Romano C, Malamisura B, Terrin G, Passariello A, Manguso F, Morelli L, Guarino A. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. May 2006. doi:10.1542/peds.2005-1655 · PMID 16651285
38. Other Rantac OD 300
39. Journal / agency Bangia AV, Kamath N, Mohan V. Ranitidine-induced thrombocytopenia: A rare drug reaction. Indian Journal of Pharmacology. February 2011. doi:10.4103/0253-7613.75676 · PMID 21455428 · PMC3062128
40. Other Ranitidine drug information
41. Other Ranitidine - core safety profile
42. Journal / agency Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, Phelps DL. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. February 2006. doi:10.1542/peds.2005-1543 · PMID 16390920
43. Journal / agency Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, Messina F, Paludetto R, Canani RB. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. January 2012. doi:10.1542/peds.2011-0796 · PMID 22157140
44. Journal / agency Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. American Journal of Health-System Pharmacy. August 2010. doi:10.2146/ajhp090477 · PMID 20689123
45. Other Earliest NDMA alert
46. Other Valisure; (and FDA CDER). Requests FDA to issue a regulation, revise industry guidance, and request a recall and suspend sales of ranitidine from the US market and take such other actions listed in the petition --Valisure FDA Petition, Attachments (and responses)
47. Journal / agency Zantac (ranitidine): Safety Information - NDMA Found in Samples of Some Ranitidine Medicines. 12 September 2019
48. Other Health Canada requests that companies stop distributing ranitidine drugs in Canada while it assesses NDMA; additional products being recalled - Recalls and safety alerts. 26 September 2019
49. Journal / agency EMA to review ranitidine medicines following detection of NDMA. 13 September 2019
50. Journal / agency FDA updates and press announcements on Angiotensin II Receptor Blocker (ARB) recalls (Valsartan, Losartan, and Irbesartan). 20 September 2019
51. Journal / agency Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) method for the determination of NDMA in Ranitidine drug substance and drug product
52. Journal / agency Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the determination of NDMA in Ranitidine drug substance and solid dosage drug product. 17 October 2019
53. Other Bomey N. Ranitidine warnings: Generic Zantac distribution halted on cancer fear. 19 September 2019
54. Other Palmer E. Novartis doesn't wait for FDA investigation and halts distribution of its generic Zantac. 19 September 2019
55. Other Sandoz ceases distribution of ranitidine product. 19 September 2019
56. Other Sandoz expands recall of antacid. 24 September 2019
57. Other Sandoz Inc. issues voluntary recall of Ranitidine Hydrochloride capsules 150mg and 300mg due to an elevated amount of unexpected impurity, N-nitrosodimethylamine (NDMA), in the product. 23 September 2019
58. Other Thomas K. Should you keep taking Zantac for your heartburn?. 19 September 2019
59. Other Carcinogen scare sets off global race to contain tainted Zantac. 18 September 2019
60. Other Comunicazione AIFA sui farmaci contenenti ranitidina
61. Other Online Nachricht: AMK: Liste der (Chargen-)Rückrufe Ranitidin-haltiger Arzneimittel. 17 September 2019
62. Other Ranitidine. 17 October 2019
63. Journal / agency Statement on new testing results, including low levels of impurities in ranitidine drugs. 1 November 2019
64. Journal / agency Laboratory tests - Ranitidine. 1 November 2019
65. Other Ranitidine - Drug Usage Statistics
66. Journal / agency Nitrosamine impurities. 6 August 2020
67. Journal / agency FDA Provides Guidance to Industry for Detecting and Preventing Nitrosamines in Drugs. 1 September 2020
68. Journal / agency Control of Nitrosamine Impurities in Human Drugs. 1 September 2020
69. Journal / agency Control of Nitrosamine Impurities in Human Drugs. September 2020
70. Journal / agency European Medicines Regulatory Network approach for the implementation of the CHMP Opinion pursuant to Article 5(3) of Regulation (EC) No 726/2004 for nitrosamine impurities in human medicines. 18 February 2021
71. Journal / agency Wang CH, Chen II, Chen CH, Tseng YT. Pharmacoepidemiological Research on N-Nitrosodimethylamine-Contaminated Ranitidine Use and Long-Term Cancer Risk: A Population-Based Longitudinal Cohort Study. International Journal of Environmental Research and Public Health. September 2022. doi:10.3390/ijerph191912469 · PMID 36231768 · PMC9566239
72. Journal / agency Apotex Corp. issues voluntary nationwide recall of Ranitidine tablets 75mg and 150mg (all pack sizes and formats) due to the potential for detection of an amount of unexpected impurity, N-nitrosodimethylamine (NDMA) impurity in the product. 26 September 2019
73. Other Heartburn drug recalled, removed from shelves over cancer concerns. 30 September 2019
74. Other Garcia SE. Zantac pulled from shelves by Walgreens, Rite Aid and CVS over carcinogen fears. 30 September 2019
75. Other CVS pharmacy statement regarding Zantac and other Ranitidine products. 3 October 2019
76. Other Kazin M. Walmart suspends sale of Zantac, other products containing ranitidine over cancer risk. 2 October 2019
77. Other Criss D. Walmart, CVS, Walgreens pull Zantac and similar heartburn drugs because of cancer worries. 30 September 2019
78. Other Edney A. Major U.S. drugstore chains pull Zantac amid carcinogen concern. 30 September 2019
79. Other Zantac recall – UK recall of Zantac (Ranitidine API), incl. Zantac Injection, Zantac Tablets, Zantac Syrup. October 2019
80. Other Class 2 Medicines recall: Zantac Injection 50mg/2ml, Zantac Syrup 150mg/10ml, Zantac Tablets 150mg, Zantac Tablets 300mg (EL (19)A 24). 8 October 2019
81. Other Zantac – MHRA drug alert issued as GlaxoSmithKline recalls all unexpired stock. 8 October 2019
82. Other Class 2 Medicines recall: Ranitidine Effervescent Tablets 150mg, Ranitidine Effervescent Tablets 300mg (EL (19)A/27). 17 October 2019
83. Other Ranitidine – MHRA drug alert issued for Teva UK recall. 17 October 2019
84. Other Class 2 Medicines recall: Ranitidine 150mg/10ml Oral Solution (EL (19)A/29). 25 October 2019
85. Other Class 2 Medicines recall: Zantac 75 Relief Tablets, Zantac 75 Tablets, Galpharm Indigestion Relief 75mg Tablets, Boots Heartburn & Indigestion Relief 75mg Tablets, Kirkland Indigestion Relief 75mg Tablets, Morrisons Indigestion & Heartburn Relief 75mg Tablets, Boots Heartburn & Indigestion Relief 75mg Tablets (EL (19)A/30). 25 October 2019
86. Other Ranitidine – MHRA drug alerts issued as Perrigo recalls prescription only and over-the-counter products. 25 October 2019
87. Other Class 2 Medicines Recall: Ranitidine Oral Solution 30mg/ml, PL 31862/0023, Ranitidine 150mg Tablets, PL 11311/0138 (EL(19)A/36). 19 November 2019
88. Other Ranitidine Oral Solution and Tablets recall. 19 November 2019
89. Other Class 2 Medicines recall: Ranitidine 75mg Tablets, (various liveries) (EL(19)A/37). 21 November 2019
90. Other MHRA drug alert: recalls for 13 over-the-counter Ranitidine medicines. 21 November 2019
91. Other Class 2 Medicines recall: Ranitidine 150mg Film-Coated Tablets, PL 20075/0063, Ranitidine 300mg Film-Coated Tablets, PL 20075/0064 (EL(19)A/40). 5 December 2019
92. Other Class 2 Medicines Recall: Medley Pharma Limited, Ranitidine 150mg Tablets BP, PL 43870/0026, Ranitidine 300mg Tablets BP, PL 43870/0027 (EL(19)A/41). 16 December 2019
93. Other Class 2 Medicines recall: Medreich PLC, Ranitidine 150mg Tablets, PL 21880/0091, Ranitidine 300mg Tablets, PL 21880/0092 (EL (20)A/05). 3 February 2020
94. Other MHRA Central Alerting System – Ranitidine: all oral formulations. Supply disruption. 15 October 2019
95. Other Thomas K. Zantac recall widens as Sanofi pulls its drug over carcinogen fears. 18 October 2019
96. Journal / agency Sanofi provides update on precautionary voluntary recall of Zantac OTC in U.S. 23 October 2019
97. Journal / agency Perrigo Company plc issues voluntary worldwide recall of Ranitidine due to possible presence of impurity, N-nitrosodimethylamine (NDMA) impurity in the product. 23 October 2019
98. Journal / agency Dr. Reddy's confirms its voluntary nationwide recall of all Ranitidine products in the U.S. market. 23 October 2019
99. Journal / agency Novitium Pharma issues voluntary national recall of Ranitidine Hydrochloride capsules 150mg and 300mg due to an elevated amount of unexpected impurity, N-nitrosodimethylamine (NDMA). 25 October 2019
100. Journal / agency Aurobindo Pharma USA, Inc. initiates voluntary nationwide consumer level recall of 38 lots of Ranitidine tablets 150mg, Ranitidine capsules 150mg, Ranitidine capsules 300mg and ranitidine Syrup 15mg/mL due to the detection of NDMA (Nitrosodimethylamine) impurity. 6 November 2019
101. Journal / agency Amneal Pharmaceuticals, LLC. issues voluntary nationwide recall of Ranitidine tablets, USP, 150mg and 300mg, and Ranitidine syrup (Ranitidine Oral Solution, USP), 15 mg/mL, due to possible presence of N-nitrosodimethylamine (NDMA) impurity. 12 November 2019
102. Journal / agency American Health Packaging issues voluntary nationwide recall of Ranitidine syrup (Ranitidine Oral Solution USP) 150 mg/10 mL liquid unit dose cups due to the detection of N-nitrosodimethylamine (NDMA) impurity. 8 November 2019
103. Journal / agency Golden State Medical Supply, Inc. issues a voluntary nationwide recall of Ranitidine hydrochloride 150mg and 300mg capsules (manufactured by Novitium Pharma LLC) due to an elevated amount of unexpected impurity, N-nitrosodimethylamine (NDMA). 15 November 2019
104. Journal / agency Precision Dose Inc. issues voluntary nationwide recall of ranitidine oral solution, USP 150 mg/10 mL due to possible presence of N-nitrosodimethylamine impurity. 19 November 2019
105. Journal / agency Glenmark Pharmaceuticals Inc., USA voluntarily recalls all unexpired lots of its Ranitidine tablets and ceases distribution, due to possible presence of N-nitrosodimethylamine (NDMA) impurity. 17 December 2019
106. Journal / agency Appco Pharma LLC issues voluntary nationwide recall of Ranitidine hydrochloride capsules 150 mg and 300 mg due to an elevated amount of unexpected impurity, N-nitrosodimethylamine (NDMA). 7 January 2020
107. Journal / agency Denton Pharma, Inc. dba Northwind Pharmaceuticals voluntarily recalls all unexpired lots of its Ranitidine tablets and ceases distribution, due to possible presence of N-nitrosodimethylamine (NDMA) impurity. 6 January 2020
108. Journal / agency American Health Packaging issues voluntary nationwide recall of Ranitidine tablets, USP 150 mg, 100 count unit dose blisters due to the detection of N-nitrosodimethylamine (NDMA) impurity. 27 February 2020
109. Journal / agency All Ranitidine Products (Zantac): Press Release - FDA Requests Removal. 1 April 2020
110. Journal / agency Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020. 30 April 2020
111. Other Ranitidine: medicine to lower stomach acid. 16 July 2021
112. Journal / agency Connelly D. Return of ranitidine being considered by UK manufacturer. The Pharmaceutical Journal. 4 October 2021
113. Journal / agency Morgan KA, Ahlawat R. StatPearls. 2023. PMID 30422583
114. Journal / agency Rogers D, Vila-Leahey A, Pessôa AC, Oldford S, Marignani PA, Marshall JS. Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response. Frontiers in Immunology. 2018-08-15. doi:10.3389/fimmu.2018.01894 · PMID 30158936 · PMC6104125
115. Journal / agency Roberts CJ. Clinical pharmacokinetics of ranitidine. Clinical Pharmacokinetics. 1984. doi:10.2165/00003088-198409030-00003 · PMID 6329583
116. Other Chronicles of Drug Discovery. 1993
117. Other Aminoalkyl furan derivatives
118. Other Brunton L, Lazo J, Parker K. Goodman & Gilman's The Pharmacological Basis of Therapeutics. August 2005
119. Journal / agency Li JJ. Beginning of an Era: The First Blockbuster Drug, Tagamet. 2014. doi:10.1093/oso/9780199737680.003.0005
120. Other Pelot, Daniel, (M.D.). "Digestive System: New Drug for Heartburn". The New Book of Knowledge: Medicine & Health, Grolier: Danbury, Connecticut. 1990. p.262.. Library of Congress 82-645223 ISBN 0-7172-8244-9
121. Journal / agency Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. The New England Journal of Medicine. March 1998. doi:10.1056/NEJM199803123381104 · PMID 9494148
122. Other Zantac Lawsuit (Drugs & Medical Devices)

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.